Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank67
5Y CAGR+50.8%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

5Y CAGR
+50.8%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
7.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$4.18M-48.5%
2024$8.12M+30.5%
2023$6.22M-
2022$0.00-
2021$0.00-100.0%
2020$537000.00+645.8%
2019$72000.00-